4D Molecular Therapeutics, Inc. (FDMT) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -68.13M | 28.55M | -46.5M | -43.38M | -47.76M | -45.86M | -29.39M | -30.24M | -29.09M | -24.65M | -1.17M | -22.07M |
| Operating CF Margin % | -2235.81% | 33.55% | -51664.44% | -289180% | -341128.57% | -4586300% | -979700% | -604860% | -103885.71% | 129736.84% | -5.8% | -9232.22% |
| Operating CF Growth % | -42.65% | 162.25% | -58.2% | -43.43% | -64.18% | -86.06% | -2409.91% | -37.06% | -4.24% | -10.97% | 94.43% | -10.86% |
| Net Income | -68.76M | 19.4M | -56.88M | -54.66M | -47.97M | -49.67M | -43.84M | -34.95M | -32.4M | -32.28M | -10.26M | -29.62M |
| Depreciation & Amortization | 2.06M | 1.98M | 2M | 1.89M | 1.75M | 1.78M | 1.7M | 1.62M | 1.59M | 1.51M | 1.4M | 1.43M |
| Stock-Based Compensation | 0 | 5.55M | 4.52M | 4.96M | 6.99M | 7.58M | 6.49M | 6.07M | 5.97M | 5.91M | 4.56M | 4.97M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -630K | 0 | 0 |
| Other Non-Cash Items | 3.33M | -1.13M | -1.14M | -1.15M | -1.35M | -1.84M | -2.2M | -2.3M | -735K | 173K | 29K | -205K |
| Working Capital Changes | -4.75M | 2.75M | 5M | 5.59M | -7.17M | -3.72M | 8.46M | -688K | -3.52M | 664K | 3.1M | 1.36M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 3.53M | 4.3M | -1.84M | 4.55M | -235K | 1.46M | -508K | -786K | 703K | -1.09M | 1.37M | 947K |
| Cash from Investing | 68.89M | -128.85M | 17.78M | -13.85M | 31.95M | 7.06M | 27.3M | -73.54M | -263.26M | -6.68M | 29.98M | 49.29M |
| Capital Expenditures | 0 | -697K | 91K | -66K | -631K | -949K | -1.78M | -349K | -710K | -549K | -405K | -805K |
| CapEx % of Revenue | - | 0.82% | 101.11% | 440% | 4507.14% | 94900% | 59266.67% | 6980% | 2535.71% | -2889.47% | 2% | 336.82% |
| Acquisitions | 11K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49.08M | 0 | -50.09M |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 767K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -49.08M | 0 | 50.09M |
| Cash from Financing | 11.48M | 111.98M | 116K | 862K | 0 | 601K | 568K | 17.25M | 318.83M | 4.76M | 10.56M | 130.52M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 11.48M | 111.98M | 0 | 862K | 0 | 601K | 1K | 15.69M | 315.72M | 1K | 8.98M | 129.72M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 116K | 0 | 0 | 0 | 567K | 1.56M | 3.11M | 4.76M | 1.58M | 799K |
| Net Change in Cash | 12.25M | 11.69M | -28.6M | -63.8M | -15.81M | -38.2M | -1.52M | -86.53M | 26.49M | -26.57M | 39.37M | 157.74M |
| Free Cash Flow | -68.13M | 27.92M | -46.41M | -43.44M | -48.39M | -46.81M | -31.17M | -30.59M | -29.8M | -25.2M | -1.58M | -22.87M |
| FCF Margin % | -2235.81% | 32.81% | -51563.33% | -289620% | -345635.71% | -4681200% | -1038966.67% | -611840% | -106421.43% | 132626.32% | -7.8% | -9569.04% |
| FCF Growth % | -40.79% | 159.64% | -48.89% | -42.01% | -62.39% | -85.77% | -1877.73% | -33.76% | -3.04% | -8.12% | 93.14% | -4.1% |
| FCF per Share | -1.00 | 0.48 | -0.83 | -0.78 | -0.87 | -0.87 | -0.56 | -0.55 | -0.60 | -0.64 | -0.04 | -0.60 |
| FCF Conversion (FCF/Net Income) | 0.99x | 1.47x | 0.82x | 0.79x | 1.00x | 0.92x | 0.67x | 0.87x | 0.90x | 0.76x | 0.11x | 0.75x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |